Abstract Number: 996 • 2013 ACR/ARHP Annual Meeting
Predictors and Modeling of Costs in Rheumatoid Arthritis
Background/Purpose: Costs in RA are substantial with 2-3 times higher mean annual costs than in the general population, but with a skewed cost distribution.[1] As…Abstract Number: 997 • 2013 ACR/ARHP Annual Meeting
Does Biologic Treatment For Rheumatoid Arthritis Offset Health Care Costs In Patients With Rheumatoid Arthritis? An Instrumental Variable Approach Using Administrative Data
Background/Purpose: Expenditure on biologic therapies for rheumatoid arthritis (RA) accounts for the highest pharmaceutical spending in many western healthcare systems. Given their clinical benefit with…Abstract Number: 998 • 2013 ACR/ARHP Annual Meeting
Adequacy Of Drug Coverage and Cost-Sharing For Medicare Beneficiaries With Rheumatoid Arthritis
Background/Purpose : Biologic and non-biologic disease-modifying anti-rheumatic drugs (DMARDs) significantly reduce pain, disability and mortality in rheumatoid arthritis (RA). We evaluated how well RA drugs…Abstract Number: 999 • 2013 ACR/ARHP Annual Meeting
Cost Consideration For Biologics For Patients With Rheumatoid Arthritis In a Pharmacy Benefit Management Setting
Background/Purpose: Of the seven biologics FDA-approved for the treatment of moderate to severe rheumatoid arthritis (RA) as of August 2011, etanercept, adalimumab, certolizumab, and golimumab…Abstract Number: 1000 • 2013 ACR/ARHP Annual Meeting
Comparison Of The Cost-Effectiveness Of The Treatment Strategies With and Without Biological Response Modifiers For Patients With Recently Diagnosed Rheumatoid Arthritis Following A Clinical Guideline For Treatment Selection
Background/Purpose: In clinical practice, management of rheumatoid arthritis (RA) is characterized by a sequence of drugs which is determined based on patient characteristics, notably disease…Abstract Number: 1001 • 2013 ACR/ARHP Annual Meeting
Long-Term Effectiveness and Cost Per Effectively Treated Patient With Biologics Used In Rheumatoid Arthritis
Background/Purpose: Previous work compared one-year cost per effectively treated patient with biologics for rheumatoid arthritis (RA) using a published, claims-based algorithm.1 Longer term comparisons are…Abstract Number: 1003 • 2013 ACR/ARHP Annual Meeting
Measuring Economic Value of Morning Stiffness; Consistency Over 1 Year
Background/Purpose: Economic evaluation of health care activities requires often measuring clinical symptoms and their changes also in monetary terms. Patients with rheumatoid arthritis (RA) may…Abstract Number: 1004 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Analysis Of Two Rituximab Based Therapeutic Regimens For Longstanding Rheumatoid Arthritis
Background/Purpose: socioeconomic costs of rheumatoid arthritis (RA) are very high. Biologic therapies with different biologic targets are now available for moderate to severe RA, and…Abstract Number: 1005 • 2013 ACR/ARHP Annual Meeting
Generalization and Extrapolation Of Treatment Effects From Clinical Studies In Rheumatoid Arthritis
Background/Purpose: Randomized clinical trials (RCTs) are accepted as the ‘gold standard’ to evaluate the efficacy/effectiveness of treatment. However, generalizing results from RCTs to daily practice…Abstract Number: 1006 • 2013 ACR/ARHP Annual Meeting
One-Year Change Of Employment and Work Productivity In Patients With Systemic Lupus Erythematosus From The Southeastern United States
Background/Purpose: Different factors influence employment and work productivity in systemic lupus erythematosus (SLE) patients, including disease activity, cognitive impairment, comorbidities, education, and psychosocial factors. Previous…Abstract Number: 1007 • 2013 ACR/ARHP Annual Meeting
Dose Of Corticosteroid, Risk Of Adverse Events and Healthcare Resource Utilization In Systemic Lupus Erythematosus
Background/Purpose: Gluco-corticosteroids (GCs) are frequently used to treat autoimmune disease and their chronic use has long been known to cause adverse events (AEs). The purpose…Abstract Number: 1008 • 2013 ACR/ARHP Annual Meeting
Longitudinal Analysis Of Direct Medical Costs For Systemic Sclerosis Patients: A Population-Based Study
Background/Purpose: Patients with systemic sclerosis (SSc) have considerable morbidity which may be associated with high health resource utilization. Studies on health use and costs are…Abstract Number: 1009 • 2013 ACR/ARHP Annual Meeting
Association Of Depressive Symptomatology and Life and Job Satisfaction In Patients With Rheumatoid Arthritis
Background/Purpose: Life satisfaction (LS) has become an important outcome measure in healthcare, is a relevant indicator of job satisfaction, and might be influenced by depression.…Abstract Number: 1010 • 2013 ACR/ARHP Annual Meeting
Association Of Depressive Symptomatology and Life and Job Satisfaction In Patients With Systemic Lupus Erythematosus
Background/Purpose: Life satisfaction (LS) has become an increasingly important outcome measure in healthcare, is a relevant indicator of job satisfaction and might be associated with…Abstract Number: 971 • 2013 ACR/ARHP Annual Meeting
A Needs Assessment and Review Curriculum Of Content Of Teaching On Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that is more common among Asians compared with Whites but the prevalence of SLE is significantly low compared with…